News | Vena Cava Filters | September 26, 2017

One-Year SENTRY Data Presented at VIVA

Bioconvertible inferior vena cava shows no new incidence of pulmonary embolism through 12 months

September 26, 2017 — The one-year results of the SENTRY clinical trial were presented by principal investigator Michael Dake, M.D., Stanford University, at the VIVA Physicians’ congress, Sept. 11-14 in Las Vegas. 

SENTRY is a prospective, single-arm, multi-center registry trial in which the safety and effectiveness of Novate Medical’s Sentry inferior vena cava (IVC) filter, the world’s first bioconvertible IVC filter, was studied. The Sentry is a new generation of IVC filter designed to provide protection from pulmonary embolism (PE) for the period of transient risk and then bioconvert to leave a patent, unobstructed IVC lumen, obviating the need to retrieve and addressing the typical filter-related complications of existing IVC filters. One hundred twenty-nine patients requiring temporary protection against PE were enrolled across 23 sites in the U.S., Europe and Chile. The rate of new symptomatic PE through 12 months was 0 percent (0/129). There were no instances of filter tilting, migration, embolization, fracture, or IVC perforation through 12 months, and there were no filter-related deaths. The rate of successful filter bioconversion was 95.7 percent (110/115) at six months and 96.4 percent (106/110) at 12 months; this is higher than the majority of published IVC filter retrieval rates.

The Sentry IVC filter received U.S. Food and Drug Administration (FDA) 510(k) clearance in February 2017.

Dake commented, “The SENTRY one-year results are compelling; a 0 percent PE rate and no filter-related complications show that the Sentry IVC filter represents an important new development in the prevention of PE.”

For more information:

Related Content

Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Cardiovascular Risk Significantly Higher in Women With Fatty Liver Disease
News | Womens Healthcare| October 20, 2017
Nonalcoholic fatty liver disease (NAFLD) is associated with significantly higher risk of subsequent cardiovascular...
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Medtronic Launches Concerto 3-D Detachable Coil System
News | Embolization devices| October 16, 2017
October 16, 2017 — Medtronic announced the launch of the Concerto 3-D Detachable Coil System at the Cardiovascular an
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Overlay Init